[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Blokhin's Russian Cancer Research Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":264},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,82,107,136,160,187,219,243],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100643563","phase-3-olanzapine-in-the-prevention-and-treatment-of-anorexia-cachexia-syndrome-in-patients-receiving-neoadjuvantpreoperative-chemotherapy-100643563",false,"NCT07633236","Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant\u002FPreoperative Chemotherapy","Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients With Localized and Locally Advanced Tumors Receiving Neoadjuvant\u002FPreoperative Chemotherapy","Inclusion Criteria:\n\n* Age ≥18 years\n* ECOG status 0-2\n* Localized\u002Flocally advanced ovarian or gastric cancer requiring neoadjuvant\u002Fpreoperative chemotherapy followed by surgery\n* Ability to consume food\u002Fmedications orally\n\nExclusion Criteria:\n\n* Olanzapine use (\\>4 days) for other indications at enrollment\n* Current use of antipsychotics\u002Fantidepressants\n* Systemic corticosteroid use (\\>7 days within the last 4 weeks)\n* History of psychiatric disorders","ALL",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","The goal of this clinical trial is to learn if olanzapine works to prevent and treat anorexia-cachexia syndrome and appetite loss in cancer patients. The main questions it aims to answer are:\n\nIs prolonged low-dose olanzapine effective and save in:\n\n* Preventing\u002Ftreating weight loss due to anorexia.\n* Controlling nausea\u002Fvomiting.\n* Maintaining anticancer therapy dose intensity?\n\nDoes prolonged low-dose olanzapine improve quality of life in patients receiving neoadjuvant\u002Fpreoperative chemotherapy?\n\nParticipants will:\n\nTake prolonged low-dose olanzapine (2.5 mg\u002Fday) in treatment group or usual diet only in control group until surgical treatment Physical examination, anthropometric assessment, blood tests, quality of life, appetite and nutritional status assessment, abdominal CT, handgrip dynamometry before chemotherapy and after preoperative chemotherapy before surgery Physical examination, adverse events every visit Surgical complications within 30 days after surgery",[25,26,27],"Oncology Patients Receiving Chemotherapy","Cachexia-Anorexia Syndrome","Oncology","RECRUITING","2026-06-03",{"date":31,"type":32},"2026-06-08","ACTUAL",{"date":34,"type":32},"2025-03-28",{"date":36,"type":19},"2027-05-31",{"name":38,"class":39},"Blokhin's Russian Cancer Research Center","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":40},"100628655","comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-gastroesophageal-cancers-100628655","NCT07464470","Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers","Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers (GENCONCOR-2)","GENCONCOR-2","Inclusion Criteria:\n\n1. Men and women aged 18 years or older included in the GASTROBRAIN study with available clinicopathological and treatment data.\n2. Histologically confirmed gastric adenocarcinoma, esophageal carcinoma (adenocarcinoma or squamous cell carcinoma), or gastroesophageal junction adenocarcinoma.\n3. History of neurosurgical resection of brain metastases with available archival tissue material, and histological confirmation of metastatic lesion originating from gastroesophageal cancer.\n4. Availability of paired FFPE tissue samples from primary tumor and matched brain metastasis.\n\nExclusion Criteria:\n\n1. Synchronous or metachronous multiple primary malignancies involving sites other than the stomach, esophagus, or gastroesophageal junction.\n2. Primary tumor located outside the gastrointestinal tract.\n3. Histologically confirmed non-epithelial gastrointestinal malignancy (e.g., neuroendocrine tumors, sarcoma, gastrointestinal stromal tumor, lymphoma).\n4. Intact brain parenchyma (e.g., metastases confined to skull bones or soft tissues of the head without brain parenchymal involvement).\n5. Insufficient tumor material or poor sample quality for molecular analysis, defined as:\n\n   * Tumor cell content \\\u003C 70% in the area of microdissection, or\n   * Significant nucleic acid degradation compromising molecular testing\n6. Missing one sample from a paired set (either primary tumor or brain metastasis unavailable).","18 Years",{"count":51,"type":19},30,"OBSERVATIONAL","GENCONCOR-2 is a translational research aimed to compare the molecular profile of primary tumors and their matched brain metastases in gastroesophageal cancers, including cancer of the esophagus, gastroesophageal junction, and stomach. The study is based on the previously established international GASTROBRAIN cohort (ClinicalTrials.gov ID: NCT07448493), which provides comprehensive clinicopathological and treatment data for over 230 patients. It will be conducted by retrospective analysis of paired samples of histological material (primary tumor and corresponding brain metastasis) with determination of HER2 expression status (IHC ± FISH), MSI status (IHC ± PCR), PD-L1 combined positive score (CPS), and CLDN18.2 expression status (IHC)",[55,56,57],"Gastric Cancer","Esophageal Cancer","Brain Metastases",[55,56,59,57,60,61,62,63,64,65,66,67,68,69,70,71,72,73],"Gastroesophageal junction cancer","Brain metastasis","Central nervous system metastases","CNS","Overall survival","OS","Time to intracranial progression","TTIP","CNS-PFS","HER2","MSI","PD-L1","CPS","CLDN18.2","Translational research","2026-03-10",{"date":76,"type":32},"2026-03-12",{"date":78,"type":19},"2026-04-01",{"date":80,"type":19},"2028-10-01",{"name":38,"class":39},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":20,"phases":92,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":40},"100614546","a-study-to-assess-the-efficiency-of-trastuzumab-deruxtecan-in-russian-breast-cancer-patients-100614546","NCT07281001","A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients","Traderrus","Inclusion Criteria:\n\n1. Patients aged over 18 years old.\n2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.\n3. Patients has received Trastuzumab Deruxtecan\n4. Available medical history.\n\nExclusion Criteria:\n\n1. Incomplete medical history.\n2. Pregnancy or breast-breeding","80 Years",{"count":91,"type":19},60,[93],"NA","This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation",[96,97],"HER2-positive Breast Cancer","Trastuzumab Deruxtecan",[97,96],"2025-12-11",{"date":101,"type":32},"2025-12-15",{"date":103,"type":19},"2025-12",{"date":105,"type":19},"2026-05",{"name":38,"class":39},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":114,"minAge":49,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":20,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100601186","phase-2-camrelizumab-in-combination-with-chemotherapy-as-neoadjuvant-treatment-in-patients-with-early-or-locally-advanced-triple-negative-breast-cancer-100601186","NCT07107217","Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer","Camella","Inclusion Criteria:\n\n1\\) 18-65 Years, female; 2) Histologically documented Triple Negative Breast Cancer (TNBC) patients; 3) Previously untreated non-metastatic (M0) TNBC, T3-4NanyM0 или TanyN+M0 3) Promising radical surgical treatment; 4) At least one measurable lesion according to RECIST 1.1; 5) Life expectancy is not less than 3 months; 6) ECOG: 0～1; 7) Adequate function of major organs meets the following requirements:\n\n8\\) Neutrophils ≥ 1.5×10\\^9\u002FL Hemoglobin ≥ 90g\u002FL Platelets ≥ 100×10\\^9\u002FL Total bilirubin≤ 1.5 × the upper limit of normal (ULN) ALT and AST ≤ 2.5 × ULN Serum creatinine ≤1.5 × ULN, Endogenous creatinine clearance ≥50mL\u002Fmin;\n\n9\\) Left ventricular ejection fraction (LVEF) ≥50% or ≥ limit of normal (LLN) was evaluated by echocardiography (ECHO) or Multigated Acquisition (MUGA); 10) Women with childbearing potential who are must agree to take effective contraceptive measures during the study period and ≥120 days after the last administration of the study drug, and must have a negative serum pregnancy test result within 7 days prior to initiation of study drug.\n\n11\\) The patient voluntarily joined the study, signed an informed consent form, had good compliance, and cooperated with follow-up;\n\nExclusion Criteria:\n\n1. Has participated in an interventional clinical study with an investigational compound within 4 weeks prior to initiation of study treatment;\n2. Prior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies;\n3. Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer;\n4. Active or history of autoimmune disease or immune deficiency diseases except history of autoimmune-related hypothyroidism, controlled Type 1 diabetes mellitus;;\n5. Has a history of (non-infectious) pneumonitis, interstitial lung disease or uncontrollable systematicness diseases, including pulmonary fibrosis, acute lung disease, etc.;\n6. Administration of a live attenuated vaccine within 30 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study;\n7. Has active infection (CTCAE≥2) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment;\n8. Has a history of serious cardiovascular disease, including myocardial infarction, acute coronary syndrome or coronary angioplasty\u002Fstent implantation\u002Fbypass grafting history in the past 6 months, and have level II-IV congestion Heart failure (CHF), or III NYHA and IV CHF history;\n9. Prior allogeneic stem cell or solid organ transplantation\n10. History of neurological or psychiatric disorders, including schizophrenia, severe depressive disorder, bipolar disorder, etc.;\n11. Subjects with a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n12. History of severe hypersensitivity reactions to other monoclonal antibodies, or intravenous infusion, or Doxorubicin, or cyclophosphamide, or paclitaxel, or carboplatine\n13. Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial;\n14. Any other situation evaluated by researchers.","FEMALE","65 Years",{"count":117,"type":19},40,[119],"PHASE2","To explore the application of Camrelizumab with chemotherapy as neoadjuvant treatment of early-stage TNBC. Phase II clinical study of Camrelizumab in neoadjuvant treatment of early-stage TNBC is proposed. The study aims to evaluate the efficacy and safety of Camrelizumab and to provide a new treatment option for neoadjuvant treatment of early-stage TNBC.",[122],"Breast Cancer",[124,125,126],"Early Breast Cancer","Neoadjuvant Therapy","Camrelizumab","NOT_YET_RECRUITING","2025-08-13",{"date":130,"type":32},"2025-08-17",{"date":132,"type":19},"2025-08",{"date":134,"type":19},"2027-12",{"name":38,"class":39},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":144,"conditions":145,"keywords":151,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":40},"100550662","comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-colorectal-cancer-100550662","NCT06449989","Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer","GENCONCOR-1","Inclusion Criteria:\n\n1. Men and women over 18 years of age.\n2. Histologically confirmed cancer of the colon or rectum.\n3. Histologically confirmed metastatic lesion of the brain.\n4. Neurosurgical resection for brain metastases of colorectal cancer.\n5. Presence of paired tumor samples (both primary tumor and intracranial material).\n\nExclusion Criteria:\n\n1. Missing one sample from a pair of tumor samples.\n2. Low quality or lack of tumor material for molecular genetic research.",{"count":51,"type":19},"GENCONCOR-1 study is translational research aimed to investigate the concordance of the molecular genetic profile of the primary tumor and brain metastases (BM) of colorectal cancer (CRC). The study was conducted by post hoc analysis of pairs of samples of histological material with determination of the mutational status of genes KRAS, NRAS, BRAF, HER2 and MSI.",[146,147,148,149,150,69],"Colorectal Cancer Metastatic","Brain Metastases, Adult","Ras (KRAS or NRAS) Gene Mutation","BRAF Gene Mutation","HER2 Gene Mutation",[146,147,148,149,150,69],"2025-08-07",{"date":154,"type":32},"2025-08-12",{"date":156,"type":32},"2024-04-01",{"date":158,"type":19},"2027-09",{"name":38,"class":39},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":20,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":40},"100591282","phase-2-a-study-of-dabrafenib-plus-cetuximabpanitumumab-with-folfox-in-the-first-line-of-therapy-in-people-with-metastatic-colorectal-cancer-100591282","NCT06978400","A Study of Dabrafenib Plus Cetuximab\u002FPanitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer","Non-randomised, Multicentre, Prospective, Single-arm, Phase II Study of the Efficacy and Toxicity of a Combination of FOLFOX With Dabrafenib and Cetuximab\u002FPanitumumab in the First Line of Therapy of Patients With Metastatic BRAF V600E- Mutated MSS Colorectal Cancer","Inclusion Criteria:\n\n* Histologically confirmed colorectal adenocarcinoma that contains MSS and BRAF V600E mutation\n* Metastatic inoperable colorectal cancer\n* Adequate function of hematopoiesis and basic indicators of internal organs\n* Has measurable or evaluable disease according to Response Evaluation Criteria In Solid Tumors (RECIST v1.1).\n* Lacking antitumor systemic treatment for colorectal cancer.\n* Patients with progression after adjuvant chemotherapy may be included if progression is recorded no earlier than 12 months after the last course of chemotherapy.\n* The primary tumor is removed or asymptomatic.\n* Absence of grade 2 or higher neuropathy.\n* Absence of tumor MSI or dMMR.\n* ECOG PS 0-2\n\nExclusion Criteria:\n\n* Participants having more than 2 lines of treatment (a progression of disease within 12 months of the completion of adjuvant and\u002For perioperative chemotherapy with oxaliplatin and fluoropyrimidines is acceptable).\n* Presence of any other malignancy, except radically treated basal cell carcinoma, cervical cancer in situ, currently or within 5 years prior to enrolment.\n* Pregnant and breastfeeding women.\n* Male and female patients with preserved reproductive potential who refused to use adequate contraception throughout the study.\n* HIV-infected patients.\n* Patients with a life expectancy of less than 3 months.\n* The presence of a disease or condition that, in the opinion of the investigator, prevents the patient from participating in the trial.",{"count":168,"type":19},64,[119],"The purpose of this study is to evaluate the efficacy and toxicity of FOLFOX regimen with dabrafenib and cetuximab\u002Fpanitumumab in the first line of therapy for the potential treatment of colorectal cancer that: has a metastatic, inoperable; has a mutation in the BRAF gene and MSS.\n\nParticipants in this study will receive one of the following study treatments:\n\nThese participants will receive FOLFOX regimen with dabrafenib and cetuximab or panitumumab in the first line of therapy This study is currently enrolling participants who will receive either FOLFOX regimen with dabrafenib and cetuximab or panitumumab in the first line of therapy.\n\nThe study team will monitor how each participant responds to the study treatment for up to about 3 years.",[172],"Neoplasms",[174,175,176,177,178],"metastatic colorectal cancer","BRAF V600E- mutated","first line","MSS","treatment","2025-05-11",{"date":181,"type":32},"2025-05-18",{"date":183,"type":32},"2025-03-01",{"date":185,"type":19},"2028-07-10",{"name":38,"class":39},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":20,"phases":198,"briefSummary":199,"conditions":200,"keywords":205,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":40},"100511457","phase-3-prophylactic-mesh-placement-during-stoma-closure-after-low-anterior-resection-100511457","NCT05939687","Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection","Prophylactic Mesh Placement During Temporary Stoma Closure: a Prospective Randomized Phase III Clinical Trial","ProMeLAR","Inclusion Criteria:\n\n* Signed informed consent\n* Absence of distant metastases (M0)\n* ECOG (Eastern Cooperative Oncology Group) status 0-2\n* completed course of adjuvant treatment\n* Absence of acute inflammatory parastomal complications\n* Integrity of colorectal anastomosis\n\nExclusion Criteria:\n\n* Inability to obtain consent to participate\n* Synchronous and metachronous malignant neoplasms\n* Clinically significant diseases of the cardiovascular system, liver, kidney, central nervous system\n* Parastomal inflammation and other conditions that increase the risk of postoperative complications\n* Pregnancy\n* HIV infection","85 Years",{"count":197,"type":19},142,[22],"The goal of this clinical trial is to compare the efficacy of using polypropylene mesh for hernia prevention after stoma closure in patients with colorectal cancer and non-mesh repair. The main question it aims to answer is: can mesh help prevent hernia? Participants will be divided into 2 groups: with and without mesh using. They must be followed up for 2 years after enrollment in the study.\n\nResearchers will compare mesh and non-mesh groups to evaluate the benefits and harms of mesh using in hernia prevention.",[201,202,203,204],"Neoplasms Malignant","Rectal Cancer","Hernia Incisional","Surgery",[206,207,208,209,210],"Rectal cancer","mesh","stoma-site hernia","prevention","surgery","2024-08-06",{"date":213,"type":32},"2024-08-07",{"date":215,"type":32},"2023-06-05",{"date":217,"type":19},"2028-12-01",{"name":38,"class":39},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":226,"sex":16,"minAge":49,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":20,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":240,"leadSponsor":242,"locationsCount":40},"100543442","a-prospective-clinical-study-on-the-safety-and-efficacy-of-radiofrequency-ablation-for-the-treatment-of-patients-with-desmoid-tumors-100543442","NCT06355921","A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors","RFAdesmoid","Inclusion Criteria:\n\n1. Patients with histologically verified diagnosis of dermoid tumor\n2. The presence of progressive, symptomatic or functionally significant DF.\n3. Written Informed consent to participate in the study\n4. Age from 18 to 75 years\n5. The functional status of the patient according to the ECOG 0-2 scale\n6. Normal renal function (estimated creatinine clearance 60 ml\u002Fmin);\n7. Normal level of bilirubin and liver enzymes (AST, ALT - no more than 3 norms);\n8. Left ventricular ejection fraction \\> 55%\n9. Satisfactory bone marrow function (hemoglobin level 9 g\u002Fdl, neutrophil count 1.5 thousand\u002Fml, platelet count \\< 100 thousand\u002Fml);\n\nExclusion Criteria:\n\n1. The inability to obtain informed consent to participate in the study\n2. Synchronous or metachronous cancer\n3. Clinically significant diseases of the cardiovascular system\n4. Clinically significant CNS diseases\n5. Previous grade 2 polyneuropathy and above\n6. Current infection or other severe or systemic disease that increases the risk of complications of therapy\n7. Pregnancy, lactation",true,"75 Years",{"count":229,"type":19},27,[93],"This is a prospective study on the safety and effectiveness of radiofrequency ablation in patients with desmoid tumors.\n\nIn the study group, all patients after radiofrequency ablation of the tumor after 1 month will be evaluated using MRI and CT studies and, if solid components of the tumor are detected, repeated surgical treatment is performed followed by active monitoring after 1 month.\n\nIn the absence of a solid component, the effect is estimated by the volume of the necrotic process and monitored in dynamics every 3 months.",[233,234,235],"Desmoid Tumor","Desmoid Fibromatosis","Desmoid","2024-04-03",{"date":238,"type":32},"2024-04-10",{"date":156,"type":19},{"date":241,"type":19},"2028-05-01",{"name":38,"class":39},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":226,"sex":16,"minAge":49,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":20,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":40},"100481325","phase-3-the-efficacy-of-neoadjuvant-chemoradiotherapy-in-comparison-with-neoadjuvant-chemotherapy-in-patients-with-resectable-squamous-cell-esophageal-cancer-100481325","NCT05547529","The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer","An Open-Label Randomized Clinical Trial to Evaluate the Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer cT3-4aN0M0, cT1-4aN1-3M0.","Inclusion Criteria:\n\n* Written informed consent.\n* Histologically confirmed squamous cell carcinoma of the esophagus.\n* Clinical stage cT1-4aN1-3M0 (AJCC\u002FUICC 8th Edition).\n* Indications for surgical esophageal resection\n* ECOG status 0-1.\n* Adequate bone marrow function (White Blood Cells \\> 3.0 x 109\u002FL; Neutrophil \\> 2.0 × 109\u002FL; Hemoglobin \\> 90 g\u002FL; Platelets \\> 100 x 109\u002FL).\n* Adequate liver function (Total bilirubin \\\u003C 1.5 x Upper Level of Normal (ULN); Aspartate transaminase (AST) and Alanine transaminase (ALT) \\\u003C 3.0 x ULN);\n* Adequate renal function (Glomerular filtration rate (CCr) \\> 50 ml\u002Fmin.\n* Adequate cardiac function. Left ventricular ejection fraction \\> 50%.\n* Age from 18 years to 70\n\nExclusion Criteria:\n\n* Clinical stage cT4bcN0cM0 (AJCC\u002FUICC 8th Edition).\n* Patients with advanced non-operable or metastatic esophageal cancer.\n* Patients who have received or are receiving other chemotherapy, radiotherapy or targeted therapy.\n* Patients with another previous or current malignant disease.\n* Allergy or contraindications to Paclitaxel, Carboplatin, Docetaxel, Cisplatin or Fluoruracil.\n* Patients with active infection of immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); HIV seropositivity; HBV DNA or HCV RNA positive.\n* Severe concomitant diseases (uncontrolled arterial hypertension, diabetes mellitus, stroke less than 6 months old, mental disorders, other tumors, etc.).\n* Clinically significant coronary artery disease (NYHA III \u002F IV), congestive heart failure (NYHAIII \u002F IV), clinically significant cardiomyopathy, myocardial infarction within the last 6 months, or high risk of uncontrolled arrhythmia.\n* Chronic inflammatory diseases of the gastrointestinal tract\n* Acute infectious diseases.\n* Pregnancy or breast feeding.\n* Serious concomitant physical and mental illness \u002F abnormalities or territorial reasons that may prevent the patient from participating in the protocol and adherence to the protocol schedule.\n* Foreigners or persons with limited legal rights.\n* Any medical, geographic, or social circumstance, that in the opinion of the investigator excludes the patient's participation in the protocol.","70 Years",{"count":252,"type":19},156,[22],"The purpose of this study is to evaluate the safety, feasibility and outcomes of neoadjuvant chemotherapy followed by esophagectomy versus neoadjuvant chemoradiotherapy followed by esophagectomy for locally advanced resectable esophageal squamous cell carcinoma cT3-4aN0M0, cT1-4aN1-3M0. This is non-inferiority study (neoadjuvant chemoradiotherapy has no advantage over neoadjuvant chemotherapy).",[56],"2022-10-02",{"date":258,"type":32},"2022-10-04",{"date":260,"type":32},"2022-09-14",{"date":262,"type":19},"2027-09-14",{"name":38,"class":39},""]